Emerging

Manatt Enhances Blockchain and Emerging Companies Capabilities With East Coast Arrival

Retrieved on: 
Thursday, June 13, 2024

Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, today announced the arrival of Financial Services Partner Mike Katz in the Firm’s New York office.

Key Points: 
  • Manatt, Phelps & Phillips, LLP, a multidisciplinary, integrated professional services firm, today announced the arrival of Financial Services Partner Mike Katz in the Firm’s New York office.
  • He also strengthens the Firm’s work with startups, emerging companies and venture investment funds operating at the cutting-edge of innovation, including in cryptocurrency, blockchain, fintech, artificial intelligence and other emerging technologies.
  • He has served as a trusted counsel to tech companies and venture funds providing legal, strategic and operational guidance at all stages of growth.
  • I look forward to leveraging my varied in-house, corporate and regulatory skills to further enhance the Firm’s reputation as the go-to adviser for companies at the frontlines of innovation.”

Mirantis Collaboration with Pure Storage Simplifies Data Management with Kubernetes

Retrieved on: 
Thursday, June 6, 2024

Mirantis is a Foundation member of Pure Storage's Technical Alliance program, enhancing the companies’ collaboration in support of their joint customers’ computing environments.

Key Points: 
  • Mirantis is a Foundation member of Pure Storage's Technical Alliance program, enhancing the companies’ collaboration in support of their joint customers’ computing environments.
  • By integrating with the Kubernetes API, Portworx automates storage operations, such as dynamic provisioning of persistent volumes on-demand for applications.
  • "Our integration with Portworx by Pure Storage is a significant step forward in simplifying persistent container storage for enterprises," said Shaun O’Meara, chief technology officer, Mirantis.
  • "With Mirantis, we're enabling enterprises to unlock the true potential of Kubernetes data, driving innovation and agility across their infrastructure while eliminating time-intensive storage management and maintenance using self-service for storage," said Louis Vitiello, director of Emerging Alliances & Technology Alliance Program, Pure Storage.

4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MA

Retrieved on: 
Thursday, May 16, 2024

The event will be hosted in the historic downtown center at the iconic Revere Hotel Boston Common, 200 Stuart Street, Boston, MA 02116.

Key Points: 
  • The event will be hosted in the historic downtown center at the iconic Revere Hotel Boston Common, 200 Stuart Street, Boston, MA 02116.
  • The conference has focus on research and development of psychedelics for various health conditions with considerable unmet need including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder.
  • This distinctive event is curated to optimize business efficacy and impart invaluable practical guidance for collaborative partnerships among disparate disciplines with common objectives.
  • Attendees have the unique opportunity to delve into developments at the cutting-edge of psychedelic therapeutics while select researchers present their studies during highly innovative scientific poster sessions.

Donaldson Employees Recognized at May 13, 2024, Patent Recipient and Inventor Awards

Retrieved on: 
Tuesday, May 14, 2024

Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, celebrated its 2024 patent recipients and Inventor Award winners.

Key Points: 
  • Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions, celebrated its 2024 patent recipients and Inventor Award winners.
  • One hundred individuals were recognized this year for their valuable contributions to Donaldson’s innovative leadership in technology-led filtration products and solutions.
  • Each year, Donaldson honors past and present employees whose work helps solve the world’s most complex filtration challenges.
  • “The employees responsible for the research and work behind each patent are key to Donaldson’s persistent leadership in global engineering, technology and the development of innovative solutions,” said Michael Wynblatt, Donaldson chief technology officer.

Human-Centered Digital Technology Starts with Digital Talent Development: DigiBridge Digital Talent Development Side Event at the 2024 UN STI Forum

Retrieved on: 
Saturday, May 11, 2024

A key highlight of the forum was the DigiBridge side event, organized by the World Digital Technology Academy (WDTA).

Key Points: 
  • A key highlight of the forum was the DigiBridge side event, organized by the World Digital Technology Academy (WDTA).
  • The event centered on crucial discussions about narrowing the global talent and skill gap and enabling developing countries to leverage digital technologies for sustainable growth.
  • Yale Li, Co-Founder and Executive Chairman of WDTA, introduced the highly anticipated 'DigiBridge Digital Talent Development Program.
  • The success of the DigiBridge side event at the 2024 UN STI Forum underscored the critical importance of international collaboration in tackling challenges of the digital era.

NCPDP Announces its 2024 Champion Award Recipient at #NCPDP24

Retrieved on: 
Wednesday, May 8, 2024

SCOTTSDALE, Ariz., May 8, 2024 /PRNewswire-PRWeb/ -- Today at its Annual Technology & Business Conference, NCPDP announced its 2024 Champion Award recipient, Shelly Spiro, Executive Director at Pharmacy HIT Collaborative and President and CEO of Spiro Consulting. NCPDP's Champion Award recognizes outstanding accomplishments or work to improve patient care by actively supporting NCPDP members and its initiatives.

Key Points: 
  • SCOTTSDALE, Ariz., May 8, 2024 /PRNewswire-PRWeb/ -- Today at its Annual Technology & Business Conference, NCPDP announced its 2024 Champion Award recipient, Shelly Spiro, Executive Director at Pharmacy HIT Collaborative and President and CEO of Spiro Consulting.
  • NCPDP's Champion Award recognizes outstanding accomplishments or work to improve patient care by actively supporting NCPDP members and its initiatives.
  • NCPDP President & CEO Lee Ann Stember stated, "We are pleased to present this award to Shelly, a long-time participant of NCPDP, Work Group Co-Chair and Leader of multiple Task Groups.
  • For real-time updates during the conference, follow @NCPDP on X, NCPDP on LinkedIn, or join the discussion using the hashtag: #NCPDP24.

Sara Rouhi joins AIP Publishing as Director of Open Science and Publishing Innovation

Retrieved on: 
Tuesday, April 30, 2024

"AIPP has a storied history as researcher-focused non-profit committed to putting science first," Rouhi said. "I'm honored to join a leadership team not only committed to forging an equitable open science path but also deeply invested in building a workplace culture grounded in humility, experimentation, and embracing change. AIPP -- thanks to its cultural transformation and its open science investment -- stands poised to contribute meaningfully and substantively to the furthering of open science globally."

Key Points: 
  • MELVILLE, N.Y., April 30, 2024 /PRNewswire/ -- AIP Publishing (AIPP) announced today that Sara Rouhi has joined the organization in the new role of Director of Open Science and Publishing Innovation.
  • AIPP -- thanks to its cultural transformation and its open science investment -- stands poised to contribute meaningfully and substantively to the furthering of open science globally."
  • Rouhi joins AIP Publishing from Public Library of Science (PLOS) where she was Regional Director, Publishing Development, The Americas.
  • I'm thrilled that Sara will join us in driving open science innovation that truly benefits the physical sciences community."

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
Wednesday, April 24, 2024

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
Friday, April 12, 2024

The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).

Key Points: 
  • The results are focused on patients with dementia with Lewy bodies (DLB) and mild cognitive impairment (MCI).
  • A second abstract being presented describes the utility of the synuclein skin biopsy in the initial diagnosis and evaluation of Parkinsonian disorders in everyday clinical practice.
  • “All of the research that will be presented during AAN supports the groundbreaking diagnostic advances using skin biopsies to detect, quantify, and monitor neurodegenerative disease progression.
  • Details on relevant presentations are as follows:
    Essential Tremor with Parkinsonism with Normal Dopamine Transporter Imaging: Majority Have Evidence of Peripheral Synucleinopathy

Canaan Adds Accomplished Executive and Scientist, Uwe Schoenbeck, Ph.D., Along with New Capital, to Bolster its Biopharma Investment Efforts

Retrieved on: 
Wednesday, April 17, 2024

MENLO PARK, Calif., April 17, 2024 /PRNewswire/ -- Canaan, a venture capital firm that invests in entrepreneurs with visionary ideas, announced the addition of Uwe Schoenbeck, Ph.D., to its healthcare investment team as a new Venture Partner. Dr. Schoenbeck's impressive career has spanned more than 25 years in the life science and healthcare industry, as well as academia, providing him with an exceptional global network among leading research institutions, biotechnology and biopharmaceutical companies, and venture firms. He is highly regarded for his contributions in enabling and translating emerging science into breakthrough therapies, reaching from scientific collaborations, licensing, and acquisition deals to venture investing. In joining Canaan's healthcare investment team, Dr. Schoenbeck will help drive new investments and company creation from Canaan XIII, the firm's latest fund, by bringing in deep scientific and pharmaceutical perspectives, while also serving as a valuable resource to companies across the firm's existing biopharma portfolio. To this end, he has already facilitated his first investment as a member of the team, leading Canaan's participation in the recently announced $132 million Series B financing for Alterome Therapeutics and being named a member of the company's board of directors.

Key Points: 
  • Most recently, Dr. Schoenbeck served as Senior Vice President and Chief Scientific Officer Emerging Science & Innovation (ES&I) in Pfizer's Worldwide Research, Development & Medical (WRDM) division.
  • In leading ES&I, he worked to harness external breakthrough science, assets, and technologies by leveraging a broad range of partnering vehicles.
  • "It is not often that we have the opportunity to add someone of Uwe's caliber and track record to the Canaan investment team.
  • In additional news, Canaan today reported that it has expanded the size of its biopharma investment funds with the addition of more than $100 million in new capital.